@article{d1d222521313495fac10e7a3af2c09c0,
title = "Sustained perfusion of revascularized bioengineered livers heterotopically transplanted into immunosuppressed pigs",
abstract = "Implanted bioengineered livers have not exceeded three days of continuous perfusion. Here we show that decellularized whole porcine livers revascularized with human umbilical vein endothelial cells and implanted heterotopically into immunosuppressed pigs whose spleens had been removed can sustain perfusion for up to 15 days. We identified peak glucose consumption rate as a main predictor of the patency of the revascularized bioengineered livers (rBELs). Heterotopic implantation of rBELs into pigs in the absence of anticoagulation therapy led to sustained perfusion for three days, followed by a pronounced immune responses directed against the human endothelial cells. A 10 day steroid-based immunosuppression protocol and a splenectomy at the time of rBEL implantation reduced the immune responses and resulted in continuous perfusion of the rBELs for over two weeks. We also show that the human endothelial cells in the perfused rBELs colonize the liver sinusoids and express sinusoidal endothelial markers similar to those in normal liver tissue. Revascularized liver scaffolds that can maintain blood perfusion at physiological pressures might eventually help to overcome the chronic shortage of transplantable human livers.",
author = "Shaheen, {Mohammed F.} and Joo, {Dong Jin} and Ross, {Jeffrey J.} and Anderson, {Brett D.} and Chen, {Harvey S.} and Huebert, {Robert C.} and Yi Li and Bruce Amiot and Anne Young and Viviana Zlochiver and Erek Nelson and Taofic Mounajjed and Dietz, {Allan B.} and Gregory Michalak and Steiner, {Benjamin G.} and Davidow, {Dominique Seetapun} and Paradise, {Christopher R.} and {van Wijnen}, {Andre J.} and Shah, {Vijay H.} and Mengfei Liu and Nyberg, {Scott L.}",
note = "Funding Information: Miromatrix Medical Inc. is a privately funded company and owns the patent rights for the perfusion decellularization and recellularization technologies employed in this study. The research was funded by Miromatrix and a Mayo Clinic Innovation grant. J.J.R., B.D.A., A.Y., B.G.S. and D.S.D. are employees of Miromatrix. Funding Information: We thank C. Verfaillie and M. Kumar from the Stem Cell Institute Leuven, KU Leuven, Belgium for the qPCR analysis performed in the manuscript, the Mayo Clinic Microscopy and Cell Analysis Core for experimental and technical support and the Mayo Clinic Biomedical Imaging Resource for creating the 3D visualizations from CT images. We also thank L. Wentz for assistance with cell culture and J. Uzarski and M. M. Macenski for their review of and comments on the final manuscript. This work was made possible by financial support from Miromatrix, Mayo Clinic ILP grants and the National Institutes of Health (grant no. R01DK106667 to S.L.N.; grant nos. R01DK117861 and R03DK113339 to R.C.H.). Publisher Copyright: {\textcopyright} 2019, The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2020",
month = apr,
day = "1",
doi = "10.1038/s41551-019-0460-x",
language = "English (US)",
volume = "4",
pages = "437--445",
journal = "Nature Biomedical Engineering",
issn = "2157-846X",
publisher = "Nature Publishing Group",
number = "4",
}